Corient Private Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.8M | Sell |
42,250
-415
| -1% | -$135K | 0.01% | 501 |
|
|
2025
Q1 | $11.5M | Sell |
42,665
-235,901
| -85% | -$63.7M | 0.02% | 491 |
|
|
2024
Q4 | $65.5M | Buy |
278,566
+81
| +0% | +$19.1K | 0.11% | 183 |
|
|
2024
Q3 | $76.6M | Buy |
278,485
+3,749
| +1% | +$1.03M | 0.12% | 174 |
|
|
2024
Q2 | $66.8M | Buy |
274,736
+129
| +0% | +$31.3K | 0.12% | 180 |
|
|
2024
Q1 | $41M | Sell |
274,607
-89
| -0% | -$13.3K | 0.07% | 259 |
|
|
2023
Q4 | $52.6M | Buy |
274,696
+1,579
| +0.6% | +$302K | 0.1% | 213 |
|
|
2023
Q3 | $48.4M | Buy |
273,117
+588
| +0.2% | +$104K | 0.11% | 194 |
|
|
2023
Q2 | $51.8M | Sell |
272,529
-353
| -0.1% | -$67K | 0.12% | 177 |
|
|
2023
Q1 | $54.7M | Buy |
272,882
+270,010
| +9,401% | +$54.1M | 0.15% | 153 |
|
|
2022
Q4 | $683K | Buy |
+2,872
| New | +$683K | ﹤0.01% | 1040 |
|